SHIFT Invest IV Achieves €92 Million First Close – Rabo Investments Proud to Support

Rabo Investments

Utrecht, 18 July 2025 – Rabo Investments is pleased to announce its participation in the successful first close of SHIFT Invest IV, which has secured an impressive €92 million in committed capital. This marks a significant step forward in advancing climate and nature-positive innovation across Netherlands and Northwestern Europe.

At a time when global attention is divided among numerous pressing issues, the urgency to address climate change, biodiversity loss, and resource depletion has never been more critical.
SHIFT Invest IV is designed to meet this challenge head-on by investing in pioneering entrepreneurs who are building scalable, technology-driven solutions with measurable environmental and financial impact.

With over 15 years of experience in impact investing, SHIFT Invest has a strong track record of supporting early-stage ventures through to successful exits. The fund is fully aligned with SFDR Article 9 standards and is committed to driving systemic change.

Investment strategy of this deal

Stage: Proof of Concept, Seed, Series A
Business Models: Software, hardware, or hybrid
Focus Areas: Energy, Industry, Mobility, Food & Agriculture
Geography: The Netherlands and Northwestern Europe
Initial Ticket Size: €250K – €4M

SHIFT Invest IV is well on track to reach its €150 million target. Rabo Investments is proud to be part of a strong coalition of investors and ecosystem partners, including Invest-NL, Royal Schiphol Group, regional development agencies such as Oost NL, BOM, ROM Utrecht Region, NV NOM, LIOF, IFG, and knowledge institutions like Delft Enterprises, TNO Ventures, and Wageningen University & Research. The fund is also supported by European funding, family offices, and mission-driven entrepreneurs.

“We are proud to support SHIFT Invest IV in scaling the next generation of climate and nature-positive ventures. This fund exemplifies our commitment to accelerating the transition to a sustainable economy,” said Laura Alberga Berendsen, Director Fund- & Co Investments, Rabo Investments.

 

Categories: News

Tags:

Ardian provides financing to support Synova’s investment in Bishop Fleming

Ardian

Ardian, a world-leading private investment firm, has arranged a Private Credit Financing package, including Unitranche and Committed Acquisition Facilities, to support Synova’s minority investment in Bishop Fleming, a leading UK-based provider of audit, tax, accountancy and advisory services.

Founded in 1919, Bishop Fleming has achieved industry-leading double-digit organic growth over the past three years. The firm has especially focused on providing tax and audit services, with key client groups including mid-market businesses and public sector organisations, spanning a diverse range of industries. Bishop Fleming has a well-established presence in the South-West of England and the West Midlands, employing approximately 500 professionals across nine offices.

“We are pleased to collaborate with Synova in supporting Bishop Fleming in their next phase of growth. Bishop Fleming’s management team has demonstrated a robust track record of consistent organic growth whilst delivering high-quality services to clients. With its strong reputation, regional presence and ability to attract industry-leading professionals, Bishop Fleming is well positioned for continued expansion. We look forward to contributing to Bishop Fleming’s continued success and partnering with Synova on yet another investment.” Stuart Hawkins, Head of Private Credit UK, Ardian

Ardian has a 20-year track record in the Private Credit market, making it one of Europe’s longest-established players.  With offices in major financial hubs across Western Europe, the Private Credit team adopts a multi-local approach in partnering with private equity houses and management teams of high-quality companies who are targeting the next phase of business growth.  This investment comes amidst a strong period of investment activity for Ardian’s Private Credit team.

List of participants

  • Ardian (Private Credit)

    • Stuart Hawkins, Raaj Rabheru, Saam Serajian-Esfahan, Eric Hensen, Sana Mehta
  • Synova

    • Oliver Bevan, Mike Mullally

ABOUT ARDIAN

Ardian is a world-leading private investment house, managing or advising $192bn of assets on behalf of more than 1,860 clients globally. Our broad expertise, spanning Private Equity, Real Assets and Credit, enables us to offer a wide range of investment opportunities and respond flexibly to our clients’ differing needs. Through Ardian Customized Solutions we create bespoke portfolios that allow institutional clients to specify the precise mix of assets they require and to gain access to funds managed by leading third-party sponsors. Private Wealth Solutions offers dedicated services and access solutions for private banks, family offices and private institutional investors worldwide. Ardian’s main shareholding group is its employees and we place great emphasis on developing its people and fostering a collaborative culture based on collective intelligence. Our 1,080+ employees, spread across 20 offices in Europe, the Americas, Asia and Middle East are strongly committed to the principles of Responsible Investment and are determined to make finance a force for good in society. Our goal is to deliver excellent investment performance combined with high ethical standards and social responsibility.
At Ardian we invest all of ourselves in building companies that last.

Media contacts

ARDIAN

Categories: News

Tags:

Cyrus partners with PAI Partners to transform the Wealth Management marke

Bridgepoint

The Cyrus Group announces that it has entered into exclusive negotiations with PAI Partners, a leading investment firm, with a view to PAI’s acquisition of a majority stake in the company.

As part of the proposed transaction, Bridgepoint, a minority shareholder in Cyrus since 2020, will sell its stake.

This transaction marks a major milestone in Cyrus’s development and reflects a clear ambition: to transform the Wealth Management market in depth.

The private and wealth management market continues to experience strong growth, driven by the increasing internationalisation of high-net-worth clients, the rising sophistication of their needs, and the demand for comprehensive, tailored advice. In this context, Cyrus intends to pursue its growth strategy: building a comprehensive and coherent model based on mastery of wealth and financial engineering, the diversity of integrated expertise, open architecture, and a bespoke approach that places the client at the centre of every decision.

For the past 36 years, Cyrus’s distinctive model has involved associating its employees with the company’s shareholding: 70% of private managers are shareholders. The core objective is to ensure that each client benefits from long-term, personalised support delivered with greater precision, foresight and efficiency — both in France and internationally.

“By choosing PAI Partners, we are asserting our ambition to build a strong brand and to establish Cyrus as a lasting presence in the wealth management landscape through a new ‘non-banking’ segment. Cyrus is entering a new phase of consolidation in the private wealth management market, which is accelerating, and of convergence between wealth management and the family office,” said Meyer Azogui and Patrick Ganansia, Co-Presidents of the Cyrus Group, who are significantly reinvesting in the transaction.

This partnership marks a strategic and cultural turning point for Cyrus. Leveraging the strength and experience of PAI Partners, the Group will have the means to accelerate its external growth strategy in France and internationally, enhance its service offering, and further anchor the Cyrus brand at the heart of the wealth management market.

“Cyrus has established itself as the leading independent player in financial advisory and savings product distribution for high-net-worth clients in France. We are delighted to partner with Meyer Azogui, Patrick Ganansia and the management team to pursue sustainable organic growth and to position Cyrus as the reference brand in the market, while reinforcing its platform through targeted consolidation opportunities in France and Europe. This majority investment reflects PAI Partners’ strategy of forming partnerships with fast-growing companies in the real economy,” said Frédéric Stévenin, Managing Partner, and Guillaume Leblanc, Partner at PAI Partners.

Over the past five years, Bridgepoint has actively supported Cyrus’s growth and organisational development, helping to strengthen its expertise, advance new initiatives, and consolidate its integrated private wealth management model — with assets under management growing from €4 billion to over €20 billion.

“It has been a real pleasure to work with Meyer Azogui, Patrick Ganansia and the Cyrus team over the past five years as they built the leading independent private wealth management platform in France. Together, we have supported the Group’s transformation through strong organic growth, strategic acquisitions, and enhanced governance. Their vision and ambition have set new standards in the market, and we wish them every success as they embark on this next chapter alongside PAI Partners,” added Bertrand Demesse, Partner at Bridgepoint.

The transaction is subject to customary regulatory approvals and is expected to close in the second quarter of 2026.

Categories: News

Tags:

Kubrick recognised with multiple awards for excellence in data and AI partnerships

Bowmark

Previous

At the 2025 Snowflake Partner Network Awards, Kubrick was named ‘Innovation Excellence – Services Partner of the Year’. The award recognises the company’s pioneering approach to helping organisations realise value from data, AI and cloud capabilities.

Kubrick Snowflake Award

Kubrick also received the ‘Managed Service Excellence’ award at the 2025 Starburst Data Visionary Awards, acknowledging the company’s outstanding implementation expertise, customer satisfaction, and its ability to drive transformative outcomes through high-impact Starburst deployments.

Dan Anderson, strategic account director at Starburst said: “Kubrick has been an invaluable partner in supporting our clients to grow their Starburst capability and drive meaningful adoption.”

In addition, Harry Hazelwood, the capability lead in data and governance at Kubrick​, was named ‘Collibra Ranger of the Year’ at the 2025 Collibra Partner Excellence Awards. The accolade recognises outstanding leadership in helping organisations design and implement effective data governance strategies. Under Harry’s guidance, Kubrick has established a ‘Collibra Centre of Excellence’ and now has six Collibra-certified Rangers supporting more than 30 clients worldwide.

Harry Hazelwood, data management practice lead​ at Kubrick said: “I’m so proud of the partnership we’ve built between Collibra and Kubrick – this award is thanks to the support of my whole team.”

These awards reflect Kubrick’s growing impact in helping organisations harness AI and data to drive transformation, while developing the next generation of data talent.

Categories: News

Tags:

Lendscape acquires WinFactor, strengthening its US presence

Bowmark

 

PreviousNext

The strategic acquisition strengthens Lendscape’s US presence – a key growth market for secured finance – and enhances its ability to support finance providers with broader solutions and deeper expertise.

WinFactor’s existing customers will continue to receive the same high-quality service, now supported by Lendscape’s technology and resources.

Tony Davison, Chair of Lendscape said: “This acquisition represents a significant milestone in Lendscape’s growth journey. With WinFactor now part of the business, we are advancing our strategy to expand in key markets and reinforce our position as a global leader.”

Martin Morrin, CEO of Lendscape, said: “With WinFactor now part of Lendscape, we are strengthening our commitment to the US secured finance market. WinFactor has built strong relationships with American factoring businesses, and by combining that with Lendscape’s international vision and leadership, we are creating more opportunities for US finance providers to innovate and grow with confidence.”

Patrick de la Roza, CEO of WinFactor, commented: “This marks an exciting new chapter for WinFactor and our customers. Becoming part of Lendscape allows us to drive more innovation, increase resources, and support our customer base more than ever before.”

Mike Kingham, Founder and Chief Innovation Officer of WinFactor, added: “When we started WinFactor, our goal was to simplify and automate factoring for our customers. With Lendscape, that mission will expand globally – faster and with greater impact.”

 

Categories: News

Tags:

PAI Partners Enters into Exclusive Negotiations to Acquire Cyrus

PAI Partners

PAI Partners, a pre-eminent private equity firm, today announces that it has entered into exclusive negotiations to acquire a majority stake in the Cyrus Group, the leading independent wealth management brand in France, through a strategic partnership with the Cyrus management team. The management team would reinvest significantly as part of the transaction.

Cyrus is a fast-growing platform, with over €20 billion in assets under management and an expanding customer base of more than 30,000 institutional and private clients. The group has a track record of strong inflows, benefits from a resilient model with a high share of recurring revenue, and is led by an experienced management team.

Cyrus is ideally positioned to gain market share supported by the breadth of its services, its open-architecture model, and the depth of its product offering. With PAI’s support, the group would drive sustainable organic growth, increase product distribution and further build its platform through targeted consolidation opportunities across France and Europe.

The wealth management market continues to experience sustained growth driven by the internationalisation of its clients, their increasingly sophisticated needs and the search for comprehensive support. In this context, Cyrus intends to advance its growth strategy by building a comprehensive and coherent model based on the diversity of integrated expertise and a tailored, client-centric approach.

PAI is a global leader and repeat investor in Business Services, specialising in traditional investments in the Real Economy over decades. In partnering with Cyrus, the firm would leverage its strong track record of partnering with management teams to rapidly scale Business Services firms and create European and global industry leaders.

Meyer Azogui and Patrick Ganansia, Co-Presidents of the Cyrus Group, said: “This transaction is part of a clear ambition: to profoundly transform the private banking and wealth management market. With our project to partner with PAI, we are affirming our commitment to creating a strong brand and establishing Cyrus in the wealth management landscape through a new “non-banking” segment. Cyrus is entering a new phase of consolidation in the accelerating private wealth management market and the convergence of wealth management with family offices.”

Frédéric Stévenin, Co-Managing Partner, and Guillaume Leblanc, Partner at PAI, said: “Cyrus has established itself as the leading independent wealth management brand in France. We are delighted by our project to partner with Meyer Azogui, Patrick Ganansia and the management team to pursue sustainable organic growth, establish Cyrus as the leading brand in the market, and strengthen the platform through targeted consolidation opportunities in France and Europe. This proposed acquisition illustrates PAI’s strategy of partnering with fast-growing companies in the Real Economy.”

Bridgepoint, a minority shareholder in Cyrus since 2020, would sell its stake as part of this transaction. Bridgepoint has actively supported the growth and structure of the group, helping to strengthen its expertise, support its development initiatives, and affirm its integrated private wealth management model. Cyrus’ assets under management have grown from €4 billion to over €20 billion during these five years of partnership.

The transaction is subject to prior regulatory approvals and is expected to close in the second quarter of 2026.

About the Cyrus Group

With 36 years of experience and more than 25 offices in France and abroad, the group brings together more than 500 employees serving over 5,000 families. Assets under management exceed €20 billion. Within the Cyrus Group, Cyrus Herez (wealth management), Amplegest (asset management), and Eternam (real estate), and soon Flandrin (private equity, subject to the ongoing application for approval from the AMF), provide a tailored offering to a high-net-worth clientele. More information: www.cyrus.fr.

About PAI Partners

PAI Partners is a pre-eminent private equity firm investing in market-leading companies across the globe. The Firm has more than €28 billion of assets under management and, since 1994, has completed over 100 investments in 12 countries and realised more than €37 billion in proceeds from over 60 exits. PAI has built an outstanding track record through partnering with ambitious management teams where its unique perspective, unrivalled sector experience, and long-term vision enable companies to pursue their full potential – and push beyond. Learn more at www.paipartners.com.

Contacts

PAI Partners
Dania Saidam
+44 20 7297 4678

Sarah Duparc
pai_partners@havas.com
+33 (0) 6 46 72 39 99

Estelle Bleuze
pai_partners@havas.com
+33 (0) 6 73 97 94 17

Categories: News

Tags:

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

EQT Life Science

 

Electra Therapeutics EQT

  • Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with serious immunological and cancer-related diseases
  • Financing was co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and all existing investors
  • Proceeds will fund the registrational Phase 2/3 clinical study of the lead program in secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory disease with no approved therapies
  • Funding will also support expanding the lead program into hematologic cancers and establishing clinical proof-of-mechanism for a second program, with broad potential across immunology and inflammation

​​Amsterdam, The Netherlands, 22 October 2025. EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in Electra Therapeutics, a late-stage US biotechnology company developing innovative treatments for immune-mediated diseases and cancer. Electra is advancing a new class of precision medicines designed to selectively target overactive immune cells that drive disease, while preserving normal immune function. This differentiated approach has the potential to deliver more effective and durable therapies for patients affected by serious immune-mediated and inflammatory conditions.

The USD 183 million Series C will fund the global registrational Phase 2/3 clinical study of the lead program (ELA026) in secondary hemophagocytic lymphohistiocytosis (sHLH) and establish clinical proof-of-mechanism for Electra’s second program (ELA822) that has broad potential across immunology. The round was co-led by EQT Life Sciences and Nextech, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala Capital, alongside all existing investors.

sHLH is a severe and life-threatening inflammatory condition triggered by underlying diseases such as cancer, autoimmune disorders, or serious infections. It causes the immune system to go into overdrive, leading to widespread inflammation and organ failure. There are currently no FDA-approved treatments for sHLH broadly, and in cancer-associated sHLH, survival at 8 weeks is only about 50 percent with existing options. Electra’s ELA026 is an antibody targeting Signal Regulatory Proteins (SIRP), cell surface receptors found on immune cells that become overexpressed in inflammatory diseases. By precisely removing these harmful cells while sparing normal immune function, ELA026 is designed to stop the inflammatory process at its source. This approach represents a novel way to rebalance the immune system and could have broader applications across multiple immune-mediated diseases.

Early clinical data are highly encouraging. In a Phase 1b study in sHLH, ELA026 achieved 100 percent survival at 8 weeks in frontline-treated patients. While preliminary, these results support the premise that precisely depleting SIRP-expressing immune cells can rapidly restore immune balance and may represent a meaningful advance for patients with this devastating condition. ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.

“We are pleased to have the support of a distinguished group of investors who share our vision to deliver life-changing treatments for patients with underserved diseases,” said Kathy Dong, PharmD, MBA, President and CEO of Electra Therapeutics. “Our team has a proven record of translating novel biology into first-in-class breakthrough therapies, as exemplified by ELA026. With strong momentum, we are driving the pivotal study of ELA026 in sHLH forward and accelerating our second SIRP-targeted program into the clinic.”

“The Electra team has demonstrated exceptional scientific and clinical execution in advancing a first-in-class therapy for patients with no approved treatment options,” said Christoph Broja, Partner in EQT Life Sciences, who will join Electra’s board as observer. “We are impressed by the clarity of Electra’s approach and the quality of its early data, and we look forward to supporting the team as it drives its pivotal program forward and explores the broader potential of SIRP-targeted therapies to bring real innovation to patients.”

Contact

EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.

More information: https://eqtgroup.com/private-capital/eqt-life-sciences

About Electra Therapeutics

Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The company’s lead product candidate, ELA026, is a first in class monoclonal antibody that targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T lymphocytes. ELA026 is currently in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH) and is also being evaluated in additional indications. Electra is further advancing a second SIRP-targeted program, ELA822, designed to selectively deplete activated T lymphocytes, with broad potential across immunology and inflammation (I&I). For more information, please visit www.electra-therapeutics.com and follow us on LinkedIn

Categories: News

Tags:

EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

No Comments
EQT Life Science

EQT-ImCheck

  • Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck’s shareholders will be eligible to receive a payment of EUR 350 million and downstream payments,  for a total potential consideration of up to EUR 1 billion.
  • ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies.
  • EQT Life Sciences has backed ImCheck since 2017 and has provided comprehensive support beyond capital, at the board level.

EQT Life Sciences is pleased to announce that Ipsen (Euronext: IPN; ADR: IPSEY) has entered into a definitive agreement to acquire its portfolio company ImCheck Therapeutics for EUR 350 million at closing, with a total transaction value of up to USD 1 billion.

ImCheck Therapeutics, based in Marseille, France, is pioneering immuno-oncology therapies by targeting butyrophilins, a novel group of immune-regulating proteins. Its lead drug, ICT01, is being tested in acute myeloid leukemia (AML) patients who are not fit for standard treatment, with early Phase I/II trial results showing promising responses. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer.

EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level.

Vincent Brichard, Venture Partner at EQT Life Sciences, said: “We are immensely proud to have supported ImCheck’s journey to this significant acquisition by Ipsen. The transaction highlights the strength of ImCheck’s platform and exceptional leadership and team. It is also a testament to our ability to identify hidden gems and support transformative biotech companies.”

Pierre d’Epenoux, CEO of ImCheck Therapeutics, said: “This transaction is an extraordinary milestone for ImCheck and puts the spotlight on groundbreaking science originating from French academia. EQT Life Sciences’ support has extended far beyond financing – their strategic guidance and confidence in my leadership has been instrumental in our success. Together, we have advanced pioneering science from concept to late-stage clinical development, demonstrating what visionary investors and dedicated teams can accomplish together.”

Together with the Amolyt Pharma exit to AstraZeneca in 2024, EQT Life Sciences has achieved successful exits from its two portfolio companies under the France 2030 investment program – a government initiative supporting the most promising French biotech innovations. This highlights EQT Life Sciences’ expertise in identifying leading European biotech companies and turning them into global success stories.

The transaction is expected to close by the end of Q1 2026, subject to customary closing conditions, including regulatory approvals under French and U.S. regulations.

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients

More information: https://eqtgroup.com/private-capital/eqt-life-sciences

About ImCheck Therapeutics

ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. By unlocking the power of γ9δ2 T cells, ImCheck’s innovative approach has the potential to transform treatments across oncology, autoimmune, and infectious diseases.

The lead clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rationale combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Additionally, ImCheck’s pipeline compounds are progressing toward clinical development for autoimmune and infectious diseases.

The company benefits from the pioneering research of Prof. Daniel Olive (Institut Paoli Calmettes, INSERM, CNRS, Aix-Marseille University), a global leader in γ9δ2 T cells and butyrophilins, as well as the expertise of a seasoned management team and the commitment of leading French, European and U.S. investors including Kurma Partners, Eurazeo, Bpifrance through its Innobio 2 and Large Venture funds, Andera Partners, Pfizer Ventures, Gimv, EQT Life Sciences, Earlybird, Wellington Partners, Pureos Bioventures, Invus, Agent Capital, Boehringer Ingelheim Venture Fund, Alexandria Venture Investments and Blood Cancer United (previously LLS)®

For further information: https://www.imchecktherapeutics.com

Categories: News

Tags:

Gimv Life Sciences realizes successful exit with the sale of its stake in Imcheck Therapeutics to Ipsen

GIMV

Gimv announces the sale of its stake in ImCheck Therapeutics to Ipsen, marking a significant milestone for both companies. This transaction highlights Gimv’s strategic approach to valorizing investments in the life sciences sector, demonstrating how our support for scientific innovation not only creates tangible value for shareholders, but also benefits society at large by advancing the medical field through the introduction of new treatments.

ImCheck Therapeutics, a French biotechnology company, has developed a next-generation antibody pipeline with its lead program, ICT01, showing highly encouraging results in acute myeloid leukemia (AML). The Phase I/II EVICTION trial has demonstrated nearly double the treatment response compared to historical standards, positioning ICT01 as a potential new standard of care for high-risk, unfit AML patients.

Ipsen’s acquisition of all issued and outstanding shares of ImCheck Therapeutics, for a closing purchase price of 350 million euro and potential milestone payments totaling nearly 1 billion euro, reflects the significant value created by ImCheck’s team, scientific founders, and investors. This transaction validates the impact of collaborative investment in transformative healthcare solutions.

Rishabh Chawla, Principal in Gimv’s Life Sciences team declares: “Gimv is proud to have supported ImCheck’s journey from academic research to late-stage clinical development. The sale to Ipsen not only delivers substantial returns to our stakeholders but also ensures that ImCheck’s innovative therapies will reach patients worldwide, backed by Ipsen’s global development and commercialization expertise.

Bram Vanparys, Managing Partner and board member at Imcheck Therapeutics, adds: “This exit highlights Gimv’s strategy of investing in high-potential life sciences companies and partnering with visionary teams to advance medical breakthroughs. We congratulate ImCheck Therapeutics and Ipsen on this landmark transaction and look forward to seeing ICT01 and future pipeline assets make a lasting impact in oncology and beyond.

As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately 0.4 euro per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones.

The transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations.

For more information, please read the full press release from Ipsen attached.

Categories: News

Tags:

Southern Home Services Expands Texas Footprint with Acquisition of Nick’s Plumbing & Air Conditioning in Houston

Gryphon Investors

Southern Home Services, a leading residential trade service consolidator, is pleased to announce the acquisition of Nick’s Plumbing & Air Conditioning, a trusted provider of plumbing, heating and air conditioning services in the greater Houston market. This strategic acquisition marks Southern’s fourth location in Texas, strengthening its presence in one of the largest and fastest-growing home services markets in the United States.

“Nick’s Plumbing & Air Conditioning is a fantastic brand and we are excited to welcome them to the Southern family,” said Jarrod Brinker, Chief Strategy Officer for Southern Home Services. “With a large population, high humidity and high summer temperatures, Houston is one of the largest, most dynamic markets in America. This partnership positions us to continue our mission of delivering exceptional plumbing and air conditioning services to even more homeowners across the lower Southeast, Midwest and Mid-Atlantic markets.”

Owner Richard Saad shared his excitement for the next chapter: “Joining forces with Southern Home Services is an exciting step forward for our team and our customers. Southern’s resources, expertise, and commitment to excellence will allow us to continue delivering the high-quality service that Houston homeowners have trusted for years while creating new opportunities for growth and innovation.”

As Southern Home Services integrates Nick’s Plumbing & Air Conditioning into its growing network of brands, the focus will remain on preserving the company’s strong local reputation and providing a seamless experience for customers and employees alike. Nick’s will continue to operate under its current name, ensuring continuity of service and culture.

About Southern Home Services
Southern Home Services, a trusted provider of comprehensive heating, air conditioning, plumbing, and electrical services across the United States, has been enhancing home comfort and safety since 2016. Our certified professionals deliver quality solutions with exceptional customer service, upholding our core values of trust, integrity, and southern charm. We are dedicated to ensuring your home systems operate smoothly, offering reliability and peace of mind in every season. For more information, visit www.southernhomeservices.com.

Categories: News